Liraglutide Review: The First Once-Daily GLP-1 Drug for Type 2 Diabetes
Comprehensive review of liraglutide — the first once-daily GLP-1 receptor agonist — covering its pharmacology, clinical trial results, weight loss effects, and cardiovascular safety data.
Quick Facts
What This Study Found
Comprehensive review of liraglutide — the first once-daily GLP-1 receptor agonist — covering its pharmacology, clinical trial results, weight loss effects, and cardiovascular safety data.
Key Numbers
How They Did This
research study.
Why This Research Matters
Relevant for peptide research.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
Trust & Context
- Key Stat:
- Key finding Comprehensive review of liraglutide — the first once-daily GLP-1 receptor agonist — covering its pharmacology, clinical trial results, weight loss eff
- Evidence Grade:
- emerging evidence.
- Study Age:
- Published in 2011.
- Original Title:
- Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
- Published In:
- The American journal of managed care, 17(2 Suppl), S59-70 (2011)
- Authors:
- Bode, Bruce(2)
- Database ID:
- RPEP-01741
Evidence Hierarchy
Frequently Asked Questions
What was studied?
Liraglutide Review: The First Once-Daily GLP-1 Drug for Type 2 Diabetes
What was found?
Comprehensive review of liraglutide — the first once-daily GLP-1 receptor agonist — covering its pharmacology, clinical trial results, weight loss effects, and cardiovascular safety data.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01741APA
Bode, Bruce. (2011). Liraglutide: a review of the first once-daily GLP-1 receptor agonist.. The American journal of managed care, 17(2 Suppl), S59-70.
MLA
Bode, Bruce. "Liraglutide: a review of the first once-daily GLP-1 receptor agonist.." The American journal of managed care, 2011.
RethinkPeptides
RethinkPeptides Research Database. "Liraglutide: a review of the first once-daily GLP-1 receptor..." RPEP-01741. Retrieved from https://rethinkpeptides.com/research/bode-2011-liraglutide-a-review-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.